The E Fund Biomedical ETF (03186) saw an intraday increase exceeding 3%. As of the latest update, it was up 2.03%, trading at HK$15.05 with a turnover of HK$1.2578 million.

The broader biomedical sector has experienced a robust rebound recently, driven by multiple catalysts. According to data, the total value of Chinese out-licensing deals in the first half of this year reached $99.7 billion, approximately double the full-year 2024 figure and close to 73% of the total for 2025, with expectations for the full-year 2026 total to set a new record.

Key Factors Driving the Sector

Notably, investment and financing activity in the healthcare sector, both domestically and internationally, continues to show strong momentum. Data indicates that global biomedical financing from January to May 2026 accumulated to $14.5 billion, marking a 26% year-on-year increase.

About the ETF's Underlying Index

The E Fund Biomedical ETF closely tracks the Solactive Biomedical Select Index. This index selects 100 biopharmaceutical companies from the Hong Kong and U.S. stock markets as its components, covering regions such as China, the United States, Europe, Israel, Switzerland, and Japan. The total weight of the Hong Kong index components is fixed at 65% of the index's total weight.

Investment Strategy and Benefits

This unique dual-market structure for Hong Kong and the U.S. allows investors to simultaneously benefit from the research and development advantages of the United States and the high-efficiency, low-cost R&D benefits of China. It effectively diversifies single-market risk, enabling a truly one-click portfolio allocation strategy.